PMID- 19790173 OWN - NLM STAT- MEDLINE DCOM- 20091209 LR - 20131121 IS - 1099-1077 (Electronic) IS - 0885-6222 (Linking) VI - 24 IP - 7 DP - 2009 Oct TI - Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. PG - 574-83 LID - 10.1002/hup.1067 [doi] AB - OBJECTIVES: To evaluate the maintenance of efficacy of risperidone long-acting injectable (RLAI) in stable patients with schizophrenia or schizoaffective disorders. The prevalence of patients who met standardized remission criteria will be also evaluated as well as the predictors factors of remission according to psychopathological, psychosocial and subjective correlates. METHODS: 52-week, open-label prospective trial in 347 stable patients switching directly to RLAI from any previous antipsychotic treatment. RESULTS: One year of treatment was completed by 70% of patients. Positive and Negative Syndrome Scale (PANSS) total and subscale, Global Assessment of Functioning (GAF) and Clinical Global Impression (CGI) scores improved from baseline at each assessment visit (p < 0.001, p < 0.001 and p < 0.05, respectively). Drug Attitude Inventory 30 (DAI30) scores improved significantly from month 3 onwards. 32% of patients met sustained remission at week 52. In a logistic regression model less severe positive and negative PANSS scores at baseline predicted remission (p < 0.001). RLAI treatment was well tolerated: one-third of patients reported mild to moderate adverse events (AEs). Eleven patients (3.2%) discontinued treatment due to an AE. No significant weight gain (p = 0.093) was reported. CONCLUSIONS: RLAI treatment up to one year improved symptoms and global functioning versus baseline, indicating that an established and accepted antipsychotic therapy can enable patients with schizophrenia to achieve and maintain remission. FAU - Rossi, Alessandro AU - Rossi A AD - Department of Experimental Medicine, University of L'Aquila, Italy. alessandro.rossi@cc.univaq.it FAU - Bagala, Anna AU - Bagala A FAU - Del Curatolo, Vincenzo AU - Del Curatolo V FAU - Scapati, Francesco AU - Scapati F FAU - Bernareggi, Micaela Maria AU - Bernareggi MM FAU - Giustra, Maria Grazia AU - Giustra MG CN - Risperidone Long-Acting Trial Investigators (R-LAI) LA - eng PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Hum Psychopharmacol JT - Human psychopharmacology JID - 8702539 RN - 0 (Antipsychotic Agents) RN - L6UH7ZF8HC (Risperidone) SB - IM MH - Adult MH - Antipsychotic Agents/*administration & dosage MH - Dose-Response Relationship, Drug MH - Drug Administration Schedule MH - Follow-Up Studies MH - Humans MH - Italy MH - Logistic Models MH - Middle Aged MH - Prospective Studies MH - Psychiatric Status Rating Scales MH - Psychotic Disorders/*drug therapy MH - Retrospective Studies MH - Risperidone/*administration & dosage MH - Schizophrenia/*drug therapy MH - *Schizophrenic Psychology MH - Time Factors MH - Treatment Outcome FIR - Bertolazzi, G IR - Bertolazzi G FIR - Bianco, P IR - Bianco P FIR - Biffi, G IR - Biffi G FIR - Bogetto, F IR - Bogetto F FIR - Caporale, D IR - Caporale D FIR - Capozza, N IR - Capozza N FIR - Cappuccio, R IR - Cappuccio R FIR - Antimo, S IR - Antimo S FIR - Carbone, M IR - Carbone M FIR - Contu, A IR - Contu A FIR - Corlito, G IR - Corlito G FIR - Cucciniello, A IR - Cucciniello A FIR - Cumin, A IR - Cumin A FIR - De Iorio, P IR - De Iorio P FIR - De Vito, M IR - De Vito M FIR - Del Curatolo, V IR - Del Curatolo V FIR - Di Munzio, W IR - Di Munzio W FIR - Erlicher, A IR - Erlicher A FIR - Ferraro, A IR - Ferraro A FIR - Forti, B IR - Forti B FIR - Foti, F F IR - Foti FF FIR - Galimberti, P IR - Galimberti P FIR - Roma, G IR - Roma G FIR - Gambini, O IR - Gambini O FIR - Paolo, S IR - Paolo S FIR - Giardina, G IR - Giardina G FIR - Grignani, M IR - Grignani M FIR - Grillo, O IR - Grillo O FIR - Interlandi, G IR - Interlandi G FIR - Ionio, C IR - Ionio C FIR - Lalicata, L IR - Lalicata L FIR - Maffei, V IR - Maffei V FIR - Malara, G IR - Malara G FIR - Marchi, E IR - Marchi E FIR - Munizza, C IR - Munizza C FIR - Nuvoli, G IR - Nuvoli G FIR - Parravani, R IR - Parravani R FIR - Pezzoli, A IR - Pezzoli A FIR - Pirfo, E IR - Pirfo E FIR - Quattrocchi, V IR - Quattrocchi V FIR - Ramaciotti, F IR - Ramaciotti F FIR - Reggiani, G IR - Reggiani G FIR - Rossi, A IR - Rossi A FIR - Sbardella, A IR - Sbardella A FIR - Selvaggio, F IR - Selvaggio F FIR - Tagliamonte, S IR - Tagliamonte S FIR - Todeschini, A L IR - Todeschini AL FIR - Venanzini, R IR - Venanzini R FIR - Vender, S IR - Vender S EDAT- 2009/10/01 06:00 MHDA- 2009/12/16 06:00 CRDT- 2009/10/01 06:00 PHST- 2009/10/01 06:00 [entrez] PHST- 2009/10/01 06:00 [pubmed] PHST- 2009/12/16 06:00 [medline] AID - 10.1002/hup.1067 [doi] PST - ppublish SO - Hum Psychopharmacol. 2009 Oct;24(7):574-83. doi: 10.1002/hup.1067.